{"id":"W4393078914","doi":"10.1016/j.ejca.2024.113608","title":"Neoadjuvant pembrolizumab or placebo + chemotherapy, followed by adjuvant pembrolizumab or placebo plus endocrine therapy for early-stage high-risk ER+/HER2– breast cancer: Results from the phase 3 KEYNOTE-756 study","year":2024,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Pembrolizumab; Medicine; Stage (stratigraphy); Breast cancer; Oncology; Placebo; Chemotherapy; Internal medicine; Adjuvant; Adjuvant chemotherapy; Cancer; Immunotherapy; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001396995,0.001016262,0.002105312,0.0002805264,0.0003178986,0.0007458911,0.0006075259,0.0008739296,0.003949496],"category_scores_gemma":[0.0008297442,0.0003661821,0.001593981,0.0002990305,0.0006895436,0.0009127776,0.0002505548,0.002282842,0.0008672547],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000752281,"about_ca_system_score_gemma":0.001082945,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00105959,"about_ca_topic_score_gemma":0.004410218,"domain_scores_codex":[0.9995936,0.0002127852,0.0000209474,0.00006597905,0.00002640356,0.00008021486],"domain_scores_gemma":[0.9995571,0.0001365064,0.00008609524,0.00004341453,0.0000176369,0.0001592425],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9361245,0.01175065,0.0007582922,0.0005788851,0.001168508,0.00003690245,0.00004002576,0.0006736856,0.007337969,0.0001028932,0.001317982,0.04010971],"study_design_scores_gemma":[0.6919343,0.2920278,0.00922662,0.00009487067,0.001674914,0.0001154799,0.00005450573,0.0004988856,0.001768135,0.0002995615,0.002274596,0.00003026136],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.98338,0.009269721,0.0005345982,0.0007282545,0.0004623005,0.001030739,0.001275743,0.00009279144,0.003225724],"genre_scores_gemma":[0.9871501,0.004768324,0.001137934,0.001037009,0.0003029579,0.000905202,0.001536071,0.00002796066,0.003134629],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003949496,"threshold_uncertainty_score":0.01321238,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04050519310740351,"score_gpt":0.3783540340905074,"score_spread":0.3378488409831039,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}